HONG KONG – To get new drugs to market faster, the South Korean government has plans that could see approval periods for biopharmaceuticals cut drastically, as part of its ongoing efforts to improve regulations and prompt greater investment in the biotechnology and health care industries, increasingly seen as a key pillar of economic growth.